Dr. Newman on Advances in Axillary Surgery in Breast Cancer

Video

Lisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.

Lisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.

One of the ways that surgeons can narrow down the extent of axillary surgery that patients need following neoadjuvant chemotherapy is called targeted axillary dissection. This is an enhanced way of doing a sentinel lymph node biopsy. Many patients who receive neoadjuvant chemotherapy are receiving that chemotherapy because they have been found to have node-positive disease.

In the past, all patients with node-positive breast cancer who had metastatic disease in the axilla were recommended to undergo a full axillary lymph node dissection, which has a lot of long-term side effects, notes Newman. With targeted axillary dissection following chemotherapy in node-positive disease, surgeons are able to perform a sentinel lymph node biopsy and radiographic evaluation of the lymph node tissue to make sure that the originally metastatic lymph node has been excised.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD